CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $829 | -95.1% | 55,629 | +898.0% | 0.00% | – |
| Q1 2022 | $17,000 | -65.3% | 5,574 | -50.2% | 0.00% | – |
| Q3 2021 | $49,000 | +2.1% | 11,198 | 0.0% | 0.00% | – |
| Q2 2021 | $48,000 | +152.6% | 11,198 | +163.3% | 0.00% | – |
| Q1 2021 | $19,000 | – | 4,253 | +25.2% | 0.00% | – |
| Q4 2020 | $0 | – | 3,398 | -52.7% | 0.00% | – |
| Q3 2020 | $0 | – | 7,178 | -76.1% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 30,042 | +339.9% | 0.00% | – |
| Q4 2019 | $13,000 | +160.0% | 6,829 | +493.3% | 0.00% | – |
| Q3 2019 | $5,000 | -98.6% | 1,151 | -97.8% | 0.00% | -100.0% |
| Q2 2019 | $369,000 | +442.6% | 51,645 | +903.0% | 0.00% | – |
| Q1 2019 | $68,000 | +58.1% | 5,149 | -6.3% | 0.00% | – |
| Q4 2018 | $43,000 | 0.0% | 5,497 | +40.8% | 0.00% | – |
| Q3 2018 | $43,000 | – | 3,904 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |